NovaBridge Biosciences (NBP) Shares Outstanding (2018 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Shares Outstanding (Entity) of $95.8 million for Q4 2025, up 17.96% year-over-year from $81.2 million in Q4 2024, and up 7.4% quarter-over-quarter from $89.2 million in Q3 2025.
NovaBridge Biosciences (NBP) Shares Outstanding (2018 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Shares Outstanding (Entity) for 8 consecutive years, with $95.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 17.96% year-over-year to $95.8 million; the TTM figure through Dec 2025 stood at $95.8 million (up 17.96% YoY), while the FY2025 annual figure was $95.8 million, up 17.96% from the prior year.
- Shares Outstanding (Entity) improved to $95.8 million in Q4 2025 per NBP's latest filing, from $89.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $95.8 million in Q4 2025 and bottomed at $47.9 million in Q2 2021.
- Historically, Shares Outstanding (Entity) has averaged $72.0 million across 5 years, with a median of $81.1 million in 2024.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) decreased 9.6% — and 2023, when it soared 54.64%.
- NovaBridge Biosciences' Shares Outstanding (Entity) stood at $49.5 million in 2021, then climbed by 8.63% to $53.8 million in 2022, then jumped by 54.64% to $83.2 million in 2023, then dropped by 2.45% to $81.2 million in 2024, then rose by 17.96% to $95.8 million in 2025.
- Business Quant data shows NBP's Shares Outstanding (Entity) at $95.8 million in Q4 2025, $89.2 million in Q3 2025, and $81.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | NovaBridge Biosciences | 215.85 Mn | 215.85 Mn | - | 220.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 220.26 Mn |
| Sep 30, 2025 | 205.09 Mn |
| Jun 30, 2025 | 187.79 Mn |
| Mar 31, 2025 | 186.73 Mn |
| Dec 31, 2024 | 186.73 Mn |
| Sep 30, 2024 | 186.49 Mn |
| Jun 30, 2024 | 186.00 Mn |
| Mar 31, 2024 | 191.42 Mn |
| Dec 31, 2023 | 191.42 Mn |
| Sep 30, 2023 | 192.92 Mn |
| Jun 30, 2023 | 191.33 Mn |
| Dec 31, 2022 | 189.79 Mn |
| Jun 30, 2022 | 188.86 Mn |
| Dec 31, 2021 | 174.71 Mn |
| Jun 30, 2021 | 168.83 Mn |
| Dec 31, 2020 | 134.16 Mn |
| Sep 30, 2020 | 126.76 Mn |
| Jun 30, 2020 | 121.82 Mn |
| Dec 31, 2019 | 7.38 Mn |
| Sep 30, 2019 | 7.18 Mn |